# US 2008/0305049 A1 · Mri Contrast Agents for Diagnosis and Prognosis of Tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305049 A1
- Document ID: US20080305049A1
- Status: Published application
- Kind: A1
- Application number: 11/815,072
- Filed: 2006-01-31
- Published: 2008-12-11
- Earliest claimed: 2005-01-31
- Inventors: Hadassa Degani; David Stein
- Web page: https://patentgrep.com/patent/US20080305049A1

## CPC

- A61K 49/085: {conjugated systems}
- A61K 49/10: Organic compounds
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to bifunctional conjugates comprising a receptor ligand moiety and a metal binding moiety and complexes thereof with paramagnetic lanthanide or transition metals, and to the use of the metal complexes as contrast agents in magnetic resonance imaging (MRI) of tumors and other abnormalities.

## Claims

### Claim 1

A conjugate of the general formula I, II or III:
L is a moiety of a ligand of a receptor associated with malignant tumors or a chemotherapeutic drug moiety;
X1 is a C2-C10 hydrocarbylene chain;
X2 is phenylene or a covalent bond;
R1 to R4 in the conjugates of formulas I and II and R1 to R3 in the conjugate of formula III, each is H, (C1-C4) alkyl or CH2R7;
R5 and R6 each is H or (C1-C4) alkyl;
R7 is selected from the group consisting of —COOR8, —COO−,
—PO32− and —CONHR8;
R8 and R9 each is selected from the group consisting of H, (C1-C4) alkyl, phenyl and benzyl, wherein the phenyl or benzyl can be substituted by at least one group selected from the group consisting of halogen, (C1-C4) alkyl and OR5;
the dotted lines, when present, define that the N atom and the 2 adjacent C atoms are part of a mono- or polycyclic ring;
and metalated complexes of a conjugate of formula I, II or III, wherein R1 to R4 each is —CH2R7 and R7 is —COOR8, —COO−, PO2(R8)(R9), PO32−, PO3H2 or —P(R9)O2− with a paramagnetic lanthanide metal selected from the group consisting of Gd (III), Eu(III), Dy(III), Tb(III), Tm(III), Yb(III) and Pr(III), and of a conjugate of formula I, II or III, wherein R, to R4 each is H, (C1-C4) alkyl or —CH2R7 and R7 is as defined above, with a paramagnetic transition metal selected from the group consisting of Mn(II), Co(III), Ni(III), Fe(II) and Fe(III).

### Claim 2 (depends on 1)

A conjugate according to claim 1, wherein L is a moiety of a ligand of a steroid receptor associated with malignant tumors.

### Claim 3 (depends on 2)

A conjugate according to claim 2, wherein said steroid receptor is an estrogen receptor and said ligand is selected from the group consisting of 17β-estradiol, estrone, estriol, tamoxifen and analogs of the foregoing.

### Claim 4 (depends on 2)

A conjugate according to claim 2, wherein said steroid receptor is the progesterone receptor and said ligand is a progestin such as progesterone.

### Claim 5 (depends on 2)

A conjugate according to claim 2, wherein said steroid receptor is the androgen receptor and said ligand is testosterone.

### Claim 6 (depends on 1)

A conjugate according to claim 1, wherein L is a moiety of a ligand of a non-steroidal hormone receptor associated with malignant tumors or other abnormalities such as luteinizing hormone/human chorionic gonadotropin receptors, human growth hormone receptor, and somatostatin receptor, or L is a ligand of another receptor such as a retinoic acid receptor.

### Claim 7 (depends on 1)

A conjugate according to claim 1, wherein L is a moiety of a chemotherapeutic drug.

### Claim 8 (depends on 1)

A conjugate according to claim 1, wherein X1 is a saturated or unsaturated aliphatic C2-C10 hydrocarbylene chain optionally interrupted by at least one atom or radical selected from the group consisting of —O—, —S—, —N(R5)—, —CO—N(R5)—, —N(R5)—CO—, —COO—, —OOC—, —N═N—, —C═N—, —N═C— and phenylene; and/or optionally substituted by at least one atom or radical selected from the group consisting of halogen, —OR5, —SR5, epoxy, epithio, oxo and —COOR5, wherein R5 is H or (C1-C4) alkyl.

### Claim 9 (depends on 1)

A conjugate according to claim 1, wherein X1 is phenylene optionally substituted by one or more halogen, (C1-C4) alkyl, —OR5, —SR5, or —COOR5 groups, wherein R5 is H or (C1-C4) alkyl.

### Claim 10 (depends on 8)

A conjugate according to claim 8, wherein X1 is an unsaturated C2-C10 aliphatic chain containing one or more double and/or one or more triple bonds.

### Claim 11 (depends on 9)

A conjugate according to claim 9, wherein X1 is —C≡C— or phenylene and X2 is a covalent bond.

### Claim 12 (depends on 9)

A conjugate according to claim 9, wherein X1 is —C≡C— or phenylene and X2 is phenylene.

### Claim 13 (depends on 1)

A conjugate according to claim 1 of formula I selected from the group consisting of formulas Ia to
wherein
L is a moiety of a ligand of a receptor associated with malignant tumors or a chemotherapeutic drug moiety;
X1 is a C2-C10 hydrocarbylene chain;
R1 to R4 each is selected from the group consisting of H, (C1-C4) alkyl and —CH2R7;
R5 and R6 each is H or (C1-C4) alkyl;
R7 is selected from the group consisting of —COOR8, —COO−,
—PO32− and —CONHR8;
R8 and R9 each is selected from the group consisting of H, (C1-C4) alkyl, phenyl and benzyl, wherein the phenyl or benzyl can be substituted by at least one group selected from the group consisting of halogen, (C1-C4) alkyl and OR5;
Y is selected from the group consisting of C, N, and S;
and complexes of the conjugates of formula Ia to Ie,
wherein R1 to R4 each is —CH2R7 and R7 is —COOR8, —COO−, PO2(R)(R9), PO32−, PO3H2 or —P(R9)O2− with a paramagnetic lanthanide metal selected from the group consisting of Gd (III), Eu(III), Dy(III), Tb(III), Tm(III), Yb(III) and Pr(III), and of a conjugate of formula I, II or III, wherein R, to R4 each is H, (C1-C4) alkyl or —CH2R7 and R7 is as defined above, with a paramagnetic transition metal selected from the group consisting of Mn(II), Co(III), Ni(III), Fe(II) and Fe(III).

### Claim 14 (depends on 1)

A conjugate according to claim 1 of formula II selected from the group consisting of formulas IIa to IIe:
wherein
L is a moiety of a ligand of a receptor associated with malignant tumors or a chemotherapeutic drug;
is a C2-C10 hydrocarbylene chain;
R1 to R4 each is selected from the group consisting of H, (C1-C4) alkyl and —CH2R7;
R5 and R6 each is H or (C1-C4) alkyl;
R7 is selected from the group consisting of —COOR8, —COO−,
—PO32− and —CONHR8;
R8 and R9 each is selected from the group consisting of H, (C1-C4) alkyl, phenyl and benzyl, wherein the phenyl or benzyl can be substituted by at least one group selected from the group consisting of halogen, (C1-C4) alkyl and OR5;
Y is selected from the group consisting of C, N, and S; and complexes of the conjugates of formula IIa to IIe, wherein R1 to R4 each is —CH2R7 and R7 is —COOR8, —COO−, PO2(R8)(R9), PO32−, PO3H2 or —P(R)O2− with a paramagnetic lanthanide metal selected from the group consisting of Gd (III), Eu(III), Dy(III), Tb(III), Tm(III), Yb(III) and Pr(III), and of a conjugate of formula I, II or III, wherein R1 to R4 each is H, (C1-C4) alkyl or —CH2R7 and R7 is as defined above, with a paramagnetic transition metal selected from the group consisting of Mn(II), Co(III), Ni(III), Fe(II) and Fe(III).

### Claim 15 (depends on 1)

A conjugate according to claim 1 of formula III selected from the group consisting of formulas IIIa to IIIf:
wherein
L is a moiety of a ligand of a receptor associated with malignant tumors or a chemotherapeutic drug moiety;
X1 is a C2-C10 hydrocarbylene chain;
R1 to R3 each is selected from the group consisting of H, (C1-C4) alkyl and —CH2R7;
R5 and R6 each is H or (C1-C4) alkyl;
R7 is selected from the group consisting of —COOR8, —COO−
—PO32− and —CONHR8;
R8 and R9 each is selected from the group consisting of H, (C1-C4) alkyl, phenyl and benzyl, wherein the phenyl or benzyl can be substituted by at least one group selected from the group consisting of halogen, (C1-C4) alkyl and OR5;
Y is selected from the group consisting of C, N, and S;
and complexes of the conjugates of formulas IIIa to IIIf, wherein R1 to R3 each is —CH2R7 and R7 is —COOR8, —COO−, PO2(R8)(R9), PO32−, PO3H2 or —P(R9)O2− with a paramagnetic lanthanide metal selected from the group consisting of Gd (III), Eu(III), Dy(III), Tb(III), Tm(III), Yb(III) and Pr(III), and of a conjugate of formula I, II or III, wherein R, to R4 each is H, (C1-C4) alkyl or —CH2R7 and R7 is as defined above, with a paramagnetic transition metal selected from the group consisting of Mn(II), Co(III), Ni(III), Fe(II) and Fe(III).

### Claim 16 (depends on 13)

A conjugate according to claim 13, wherein L is a moiety of a ligand of a steroid receptor associated with malignant tumors.

### Claim 17 (depends on 16)

A conjugate according to claim 16, wherein said steroid receptor is an estrogen receptor and said ligand is selected from the group consisting of 17β-estradiol, estrone, estriol, tamoxifen and analogs of the foregoing.

### Claim 18 (depends on 16)

A conjugate according to claim 16, wherein said steroid receptor is the progesterone receptor and said ligand is a progestin such as progesterone.

### Claim 19 (depends on 16)

A conjugate according to claim 16, wherein said steroid receptor is the androgen receptor and said ligand is testosterone.

### Claim 20 (depends on 13)

A conjugate according to claim 13, wherein L is a moiety of a ligand of a non-steroidal hormone receptor associated with malignant tumors or another abnormalities such as luteinizing hormone/human chorionic gonadotropin receptors, human growth hormone receptor, and somatostatin receptor, or L is a ligand of another receptor such as a retinoic acid receptor.

### Claim 21 (depends on 13)

A conjugate according to claim 13, wherein L is a moiety of a chemotherapeutic drug.

### Claim 22 (depends on 13)

A conjugate according to claim 13, wherein X1 is a saturated or unsaturated aliphatic C2-C10 hydrocarbylene chain optionally interrupted by at least one atom or radical selected from the group consisting of —O—, —S—, —N(R5)—, —CO—N(R5)—, —N(R5)—CO—, —COO—, —OOC—, —N═N—, —C═N—, —N═C— and phenylene; and/or optionally substituted by at least one atom or radical selected from the group consisting of halogen, —OR5, —SR5, epoxy, epithio, oxo and —COOR5, wherein R5 is H or (C1-C4) alkyl.

### Claim 23 (depends on 22)

A conjugate according to claim 22, wherein X1 is an unsaturated C2-C10 aliphatic chain containing one or more double and/or one or more triple bonds, preferably —C≡C—.

### Claim 24 (depends on 13)

A conjugate according to claim 13, wherein X1 is phenylene optionally substituted by one or more halogen, (C1-C4) alkyl, —OR5, —SR5, or —COOR5 groups, wherein R5 is H or (C1-C4) alkyl.

### Claim 25 (depends on 13)

A conjugate according to claim 13 of formula Ia to Ie, wherein L is a 17β-estradiol or tamoxifen moiety, and X1 is —C≡C—.

### Claim 26 (depends on 25)

The conjugate according to claim 25 of formula Ie, wherein L is a 17β-estradiol or tamoxifen moiety X1 is —C≡C—, R1 to R3 each is —CH2R7, wherein R7 is selected from the group consisting of —COOR8, —COO−, PO2(R8)(R9), PO32−, PO3H2 and —P(R9)O2−, R4, R5 and R6 each is H, and R8 and R9 each is H or (C1-C4) alkyl, and a complex thereof with a paramagnetic lanthanide metal selected from the group consisting of Gd (III), Eu(III), Dy(III), Tb(III), Tm(III), Yb(III) and Pr(III), preferably Gd(III).

### Claim 27 (depends on 25)

The conjugate according to claim 25 of formula Ie, wherein L is 17β-estradiol or tamoxifen, X1 is —C≡C—, R1 to R4 each is —CH2COOR8 or —CH2COO−, R5 and R6 each is H and R8 is H or (C1-C4) alkyl, and a complex thereof with a paramagnetic lanthanide metal selected from the group consisting of Gd (III), Eu(III), Dy(III), Tb(III), Tm(III), Yb(III) and Pr(III, preferably Gd(III) or Eu (III).

### Claim 28 (depends on 25)

The conjugate according to claim 25 of formula Ie, wherein L is a 17β-estradiol or tamoxifen moiety, X1 is —C≡C—, and R1 to R6 each is H, and a complex thereof with a paramagnetic transition metal selected from the group consisting of Mn(II), Co(III), Ni(III), Fe(II) and Fe(III), preferably Fe(III).

### Claim 29 (depends on 14)

A conjugate according to claim 14 of formula IIa to IIe, wherein L is a 17β-estradiol or tamoxifen moiety, and X1 is —C≡C—.

### Claim 30 (depends on 29)

The conjugate according to claim 29 of formula IIe, wherein R1 to R4 each is —CH2R7, wherein R7 is selected from the group consisting of —COOR8, —COO−, PO2(R8)(R9), PO32−, PO3H2 and —P(R9)O2−, R5 and R6 each is H, and R8 is H or (C1-C4) alkyl and a complex thereof with a paramagnetic lanthanide metal selected from the group consisting of Gd (III), Eu(III), Dy(III), Tb(III), Tm(III), Yb(III) and Pr(III).

### Claim 31 (depends on 30)

The conjugate according to claim 30 of formula IIe, wherein L is a 17β-estradiol moiety, R5 and R6 each is H, and R1 to R4 each either is —CH2COO-tBut (compound 5) or —CH2COOH (compound 6).

### Claim 32 (depends on 30)

The conjugate according to claim 30 of formula IIe, wherein L is a tamoxifen moiety, R5 and R6 each is H, and R1 to R4 each either is —CH2COO-tBut (compound 14) or —CH2COOH (compound 15).

### Claim 33 (depends on 30)

The conjugate complex according to claim 30 of the conjugate of formula IIe, wherein L is a 17β-estradiol or tamoxifen moiety, R1 to R4 each is —CH2COO−, and R5 and R6 each is H, with a paramagnetic lanthanide metal selected from the group consisting of Gd (III), Eu(III), Dy(III), Tb(III), Tm(III), Yb(III) and Pr(III).

### Claim 34 (depends on 33)

The conjugate complex of claim 33, wherein said paramagnetic lanthanide metal is Gd(III) and L is 17β-estradiol (compound 7) or tamoxifen (compound 16).

### Claim 35 (depends on 15)

A conjugate according to claim 15 of formula IIIa to IIIf, wherein L a is 17β-estradiol or tamoxifen moiety, X1 is —C≡C—, R1 to R3 each is —CH2R7, wherein R7 is selected from the group consisting of —COOR8, —COO−, PO2(R8)(R9), PO32−, PO3H2 and —P(R)O2−, R5 and R6 each is H, and R8 is H or (C1-C4) alkyl, preferably H, and a complex thereof with a paramagnetic lanthanide-metal selected from the group consisting of Gd(III), Eu(III), Dy(III), Tb(III), Tm(III), Yb(III) and Pr(III), preferably Gd(III) or Eu(III).

### Claim 36 (depends on 1)

A method of using a contrast agent to obtain magnetic resonance images of a patient, comprising: administering to a patient a magnetic resonance imaging contrast agent comprising a paramagnetic metal complex of a conjugate of the formula I, II or III as defined in claim 1, and taking magnetic resonance images of the patient prior to said administration and thereafter.

### Claim 37 (depends on 1)

A molecular magnetic resonance imaging (MRI) method comprising the steps of: (i) administering to a patient a MRI contrast agent comprising a paramagnetic metal complex of a conjugate of formula I, II or III as defined in claim 1; and (ii) subjecting the patient to magnetic resonance imaging by generating at least one MR image of the target region of interest within the patient's body prior to said administration and one or more MR images thereafter.

### Claim 38 (depends on 37)

The MRI method according to claim 37 for tumor diagnosis comprising the steps of: (i) administering to a patient suspected of having a tumor said MRI contrast agent, wherein L is a moiety of a ligand of a receptor associated with said tumor; (ii) generating an MR image at zero time and at a second or more time points thereafter; and (iii) processing and analyzing the data to diagnose the presence or absence of a tumor.

### Claim 39 (depends on 37)

The MRI method according to claim 37 for prognosticating the effectiveness of a chemotherapeutic or hormonal treatment of a patient bearing a malignant tumor and being treated with a chemotherapeutic or hormonal agent, comprising the steps of: (i) administering to the patient said MRI contrast agent, wherein L is a moiety of a ligand of a receptor associated with the tumor; (ii) generating an MR image at zero time and at a second or more time points thereafter; and (iii) processing and analyzing the data to prognosticate the effectiveness of the chemotherapeutic or hormonal agent in the treatment of said tumor in said patient.

### Claim 40 (depends on 37)

The MRI method according to claim 37 for follow-up of malignant tumor therapy in a patient by a chemotherapeutic or hormonal agent, comprising the steps of: (i) administering to the patient said MRI contrast agent, wherein L is a moiety of a ligand of a receptor associated with the tumor; (ii) generating an MR image at zero time and at a second or more time points thereafter; and (iii) processing and analyzing the data to evaluate the effectiveness of the chemotherapeutic or hormonal agent in the treatment of said tumor in said patient.

### Claim 41 (depends on 37)

The MRI method according to claim 37 for monitoring a chemotherapeutic drug or an anti-hormonal agent delivery to a malignant tumor, comprising the steps of: (i) administering to the patient said MRI contrast agent, wherein L is a moiety of a ligand of a receptor associated with the tumor; (ii) generating an MR image at zero time and at a second or more time points thereafter; and (iii) processing and analyzing the data to evaluate the effectiveness of the delivery of the chemotherapeutic or anti-hormonal agent to said tumor.

### Claim 42 (depends on 36)

A method according to claim 36 wherein said tumor is breast or prostate cancer.

### Claim 43 (depends on 36)

A method according to claim 36 wherein the MRI contrast agent is the Gd(III) complex herein designated compound 7 or the Gd(III) complex herein designated compound 16.

### Claim 44 (depends on 37)

The method according to claim 37 wherein said MRI contrast agent is administered by a bolus intravenous injection.

### Claim 45 (depends on 37)

The method according to claim 37 wherein said MRI contrast agent is administered by slow infusion.

### Claim 46 (depends on 1)

An MRI contrast agent comprising a paramagnetic metal complex of a conjugate of formula I, II or III as defined in claim 1.

### Claim 47 (depends on 46)

The MRI contrast agent according to claim 46 wherein said metal complex is the Gd(III) complex compound 7 or compound 16.

### Claim at position 48

48-52. (canceled)
